3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
19
Observational
1
Sponsor
Conditions
Pain
4
Breakthrough Cancer Pain
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Sarcoma
1
Quality of Life
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Postoperative Complications
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Ovarian Neoplasms
1
Neuralgia
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Interventions
Surveys and Questionnaires
86
Blood Specimen Collection
58
Interviews as Topic
28
Observation
15
Data Collection
15
Radiotherapy
12
Watchful Waiting
11
Magnetic Resonance Spectroscopy
11
Hematologic Tests
11
Exercise
11
Drug Therapy
11
Quality of Life
9
Biopsy
8
Specimen Handling
7
Therapeutics
6
Restraint, Physical
6
Magnetic Resonance Imaging
6
Focus Groups
6
pembrolizumab
5
Standard of Care
5
Rivaroxaban
5
Phlebotomy
5
Nivolumab
5
Lapatinib
5
Immune Checkpoint Inhibitors
5
atezolizumab
4
apixaban
4
Trastuzumab
4
Patient Reported Outcome Measures
4
Palliative Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasms
×
Fentanyl
×
Clear all
NCT01946555
2016-04-14
RER
Mario Negri Institute for Pharmacological Research
Completed
150 enrolled